RUNX3 and myeloid sarcoma: To evaluate the association of RUNX3, EOMES and T-bet with brain-homing T cells in MS, we first compared the presence of these factors in CD8+ memory T subsets in the blood of healthy controls (HCs; n = 8), treatment-naive MS patients (n = 18) and MS patients who clinically responded to natalizumab (NTZ-MS; n = 8).